BioAlliance Pharma SA (Euronext Paris – BIO), a Company dedicated to orphan oncology products and specialty products, today announces the reinforcement of its development team with the appointment of Louis Kayitalire, MD, as Head of Research and Development.
Directly reporting to the CEO, member of the Strategic Committee, Louis Kayitalire will be in charge of the development strategy of BioAlliance Pharma and of the development plan implementation, from preclinical phases to registration. Preclinical, clinical and regulatory teams will consequently report to him.
« I am delighted to welcome Louis. Thanks to his high expertise in cancer drug development, his knowledge of this area and his international experience, Louis will undoubtedly contribute to strengthen dynamics in building our position in the orphan oncology product domain. Moreover, he is joining the Company at a key stage of its strategic deployment in oncology, today with three products in an active development phase and determining milestones to come in the next months. I am sure that thanks to his large experience combined with his open and enthusiastic personality, he will rapidly and efficiently succeed in integrating the team”, stated Judith Greciet, CEO of BioAlliance Pharma.
Medical oncologist from the Institut Gustave Roussy (Villejuif cancer research institute), Louis Kayitalire started his career at Eli Lilly in France and then in the United-States, before joining Bristol Myers Squibb Corporate (US) until 2007. He has collaborated to the development of several cancer drugs, from early phases to registration, of which some are today flagship cancer treatments.
Before joining BioAlliance Pharma, Louis Kayitalire was for 5 years Vice President Clinical Research for Oncology, Immunology/Inflammation and CNS/Pain at Cephalon Europe.